Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study.
Gastric cancer
Neoadjuvant chemotherapy
Retrospective study
TeFOX
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Aug 2019
15 Aug 2019
Historique:
received:
18
03
2019
revised:
07
06
2019
accepted:
20
06
2019
entrez:
23
8
2019
pubmed:
23
8
2019
medline:
23
8
2019
Statut:
ppublish
Résumé
Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results. To determine safety and efficacy of TeFOX perioperative regimen. This monocentric retrospective study aims to test efficacy and safety of the perioperative TeFOX regimen given alone or in combination with trastuzumab in patients with localized GC. TeFOX consist in docetaxel (50 mg/m²) with oxaliplatin 85 mg/m² and and leucovorin (400 mg/m Thirty-three consecutive patients were included in this retrospective study. Eighteen patients have a gastroesophageal junction cancer and 11 have a GC. Median follow-up of surviving patients was 32 mo. R0 resection was obtained in 30 (91) patients. Twelve patients (36) had a pathological complete response and 8 (24) patients a nearly complete pathological response. Median OS and PFS were not reached at data base lock. We have observed 6 metastatic relapses and 1 localized relapse. No relapse was observed in patients with pathological complete responses. The most common grade 3-4 adverse events were peripheral neuropathy (21) and asthenia (20). TeFOX regimen could be safely administrated in perioperative treatment of localized GC. TeFOX and the FLOT regimen have comparable efficacy and safety profiles.
Sections du résumé
BACKGROUND
BACKGROUND
Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results.
AIM
OBJECTIVE
To determine safety and efficacy of TeFOX perioperative regimen.
METHODS
METHODS
This monocentric retrospective study aims to test efficacy and safety of the perioperative TeFOX regimen given alone or in combination with trastuzumab in patients with localized GC. TeFOX consist in docetaxel (50 mg/m²) with oxaliplatin 85 mg/m² and and leucovorin (400 mg/m
RESULTS
RESULTS
Thirty-three consecutive patients were included in this retrospective study. Eighteen patients have a gastroesophageal junction cancer and 11 have a GC. Median follow-up of surviving patients was 32 mo. R0 resection was obtained in 30 (91) patients. Twelve patients (36) had a pathological complete response and 8 (24) patients a nearly complete pathological response. Median OS and PFS were not reached at data base lock. We have observed 6 metastatic relapses and 1 localized relapse. No relapse was observed in patients with pathological complete responses. The most common grade 3-4 adverse events were peripheral neuropathy (21) and asthenia (20).
CONCLUSION
CONCLUSIONS
TeFOX regimen could be safely administrated in perioperative treatment of localized GC. TeFOX and the FLOT regimen have comparable efficacy and safety profiles.
Identifiants
pubmed: 31435464
doi: 10.4251/wjgo.v11.i8.634
pmc: PMC6700033
doi:
Types de publication
Journal Article
Langues
eng
Pagination
634-641Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors have no conflict of interests.
Références
Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Ann Surg. 2011 May;253(5):934-9
pubmed: 21490451
Int J Cancer. 2012 Apr 1;130(7):1706-13
pubmed: 21618509
Int J Cancer. 2015 Aug 1;137(3):678-85
pubmed: 25530271
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Lancet Oncol. 2017 Mar;18(3):357-370
pubmed: 28163000
Lancet Oncol. 2017 Sep;18(9):1249-1260
pubmed: 28784312
Br J Cancer. 2018 Aug;119(4):424-428
pubmed: 29872148
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
BMC Cancer. 2019 Jan 8;19(1):38
pubmed: 30621632
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686